Onco-haematology Vigilance Card

Last updated: November 2, 2021
Sponsor: University Hospital, Limoges
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neoplasms

Treatment

N/A

Clinical Study ID

NCT04931329
87RI21_0010
  • All Genders

Study Summary

The objective of this study is to show the interest of setting up a drug vigilance card in Oncology in order to reinforce patient safety, develop compliance and avoid drug interactions when the patient consults town professionals or other specialists.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • All patients treated at Limoges University Hospital in Medical Oncology department,receiving oral treatment (chemotherapy and/or targeted therapies)

Exclusion

Exclusion Criteria:

  • All patients treated at Limoges University Hospital in Medical Oncology department,receiving hormone therapy or IV treatment only.

Study Design

Total Participants: 100
Study Start date:
November 02, 2021
Estimated Completion Date:
June 30, 2022

Study Description

Recent developments in oral chemotherapy and targeted therapies have radically changed cancer patient management; ambulatory care is now common. Oral therapies afford many advantages, improving patient quality of life and autonomy by reducing hospital stays and involving patients in their own care. Optimising the care of cancer patients at home requires the coordinated intervention of hospital and town healthcare professionals and involvement of the patient to detect, prevent, and manage adverse events, avoid drug interactions, and educate patients. Preliminary work in haematology has highlighted (n = 31 patients) the interest of a "drug vigilance card" in three indications (Chronic Lymphocytic Leukaemia, Chronic Myeloid Leukaemia and Multiple Myeloma) with an increase in the town-hospital link.

This is an prospective cohort study. Following the announcement consultation, in addition to the personalised care plan, the information about the treatment will be contained in a drug monitoring card that will be given to the patient by the health professional (doctor or nurse). This drug monitoring card should be presented to the health professionals by the patient. During the entire period of treatment, the patient will have a card.

Connect with a study center

  • CHU de Limoges

    Limoges, 87042
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.